Prestige Consumer Healthcare
About: Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Employees: 570
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
52% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 27
12% more capital invested
Capital invested by funds: $3.65B [Q3] → $4.09B (+$449M) [Q4]
12% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 110
4.2% more ownership
Funds ownership: 101.96% [Q3] → 106.15% (+4.2%) [Q4]
2% more funds holding
Funds holding: 323 [Q3] → 331 (+8) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
RBC Capital | 23%upside $97 | Sector Perform Maintained | 21 Mar 2025 |
Oppenheimer Rupesh Parikh 38% 1-year accuracy 11 / 29 met price target | 18%upside $93 | Outperform Maintained | 13 Feb 2025 |
Canaccord Genuity Susan Anderson 19% 1-year accuracy 7 / 36 met price target | 27%upside $100 | Buy Maintained | 7 Feb 2025 |
DA Davidson Linda Bolton Weiser 9% 1-year accuracy 9 / 99 met price target | 32%upside $104 | Buy Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 5 articles about PBH published over the past 30 days
